Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS

VBCC - January 2013, Volume 4, No 1 - Health Economics
Caroline Helwick

Atlanta, GA—The use of azacitidine (Vidaza) in patients with high-risk myelodysplastic syndrome (MDS) is associated with the reduced need for red blood cell (RBC) transfusion and transfusion dependence, a report from the 2012 American Society of Hematology meeting showed.

“At 12 and 18 months after azacitidine treatment, there were 26% and 38% reductions in RBC transfusion costs, respectively, per patient compared with the 6 months before therapy,” said Eric Tseng, MD, Department of Hematology, University of Toronto, Ontario, Canada.

In 2009, azacitidine was shown in the AZA001 study to improve overall survival, leukemia-free survival, and hematologic response, while reducing transfusion dependence in intermediate- and high-risk MDS, compared with conventional care. Transfusion dependence in patients with MDS is associated with greater health resource utilization and high transfusion-related costs in the inpatient and the outpatient settings. It is also associated with increased mortality, Dr Tseng said.

“Hypomethylating agents, including azacitidine, have been shown to be cost-effective in treating high-risk MDS,” he said, “but there is a lack of studies assessing the effect of azacitidine on transfusion requirements and transfusion-related costs in the real-world clinical setting.”
Using real-world data, Dr Tseng and colleagues retrospectively reviewed data of 51 patients with MDS who were treated with the approved dose and schedule of azacitidine at their tertiary care center between 2008 and 2012.

The cost per unit of RBCs was determined to be $1183 (2008 US dollars) and $1273 (2012 Canadian dollars). Transfusion costs per patient were determined for 6-month intervals before and after the initiation of azacitidine.
Substantial Decline in Transfusions and Costs

“The number of units transfused decreased in both the inpatient and outpatient settings after treatment with azacitidine was initiated,” Dr Tseng added. The number of RBC transfusions and costs declined sub­stantially between baseline and 12-
month to 18-month follow-up (shown in Canadian dollars):

  • 6 months before azacitidine:
    11 RBC units transfused; cost, $14,048
  • 0 to 6 months after azacitidine:
    10.9 RBC units; cost, $13,898
  • 6 to 12 months after azacitidine:
    8.2 RBC units; cost, $10,407
  • 12 to 18 months after azacitidine:
    6.9 RBC units; cost, $8744.

The patients in this study had similar response rates with azacitidine as those in the AZA001 trial, which were robust in approximately 66% of patients. The median number of cycles was 11, and the median time to best response was 6 months.

Overall, 63% became transfusion independent within 18 months of the initiation of azacitidine. Median time to transfusion independence was 3 months, Dr Tseng reported.

Related Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives published on August 30, 2017 in Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives published on June 26, 2017 in Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives published on March 31, 2017 in Multiple Sclerosis
Ocrelizumab Receives Breakthrough Therapy for Progressive Multiple Sclerosis
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Ozanimod Achieves Very Low Relapse Rate in MS
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Stem-Cell Transplantation Shows Promise in Multiple Sclerosis, but Major Concerns Remain
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Increased Use of Sodium Channel Blockers May Reduce Costs in Partial-Onset Seizures
Chase Doyle
VBCN - July 2015 Volume 2, No 2 published on August 5, 2015 in Health Economics
Parameters Affecting Treatment Decisions for Patients with Multiple Sclerosis
Chase Doyle
VBCN - July 2015 Volume 2, No 2 published on August 5, 2015 in Health Economics
Unemployment Status Linked to Disability in Secondary-Progressive Multiple Sclerosis
Chase Doyle
VBCN - July 2015 Volume 2, No 2 published on August 5, 2015 in Health Economics
Experts Make the Case for Putting Social Values Into Cost-Effectiveness Analyses
Rosemary Frei, MSc
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Health Economics
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology